UY35328A - Tratamiento de formas progresivas de esclerosis múltiple con laquinimod - Google Patents

Tratamiento de formas progresivas de esclerosis múltiple con laquinimod

Info

Publication number
UY35328A
UY35328A UY0001035328A UY35328A UY35328A UY 35328 A UY35328 A UY 35328A UY 0001035328 A UY0001035328 A UY 0001035328A UY 35328 A UY35328 A UY 35328A UY 35328 A UY35328 A UY 35328A
Authority
UY
Uruguay
Prior art keywords
laquinimod
multiple sclerosis
treatment
human subject
progressive forms
Prior art date
Application number
UY0001035328A
Other languages
English (en)
Spanish (es)
Inventor
Tarcic Nora
Dan Bar-Zohar
Hayardeny Liat
Yossi Gilgun Sherki
Gorfine Tali
Knappertz Volker
Sorani Ella
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51351655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY35328(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of UY35328A publication Critical patent/UY35328A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
UY0001035328A 2013-02-15 2014-02-14 Tratamiento de formas progresivas de esclerosis múltiple con laquinimod UY35328A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361765394P 2013-02-15 2013-02-15
US201361911106P 2013-12-03 2013-12-03

Publications (1)

Publication Number Publication Date
UY35328A true UY35328A (es) 2014-09-30

Family

ID=51351655

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035328A UY35328A (es) 2013-02-15 2014-02-14 Tratamiento de formas progresivas de esclerosis múltiple con laquinimod

Country Status (18)

Country Link
US (2) US20140235670A1 (enExample)
EP (1) EP2956137A4 (enExample)
JP (1) JP2016510343A (enExample)
KR (1) KR20150119227A (enExample)
CN (1) CN105163737A (enExample)
AU (1) AU2014216199A1 (enExample)
BR (1) BR112015019564A2 (enExample)
CA (1) CA2900503A1 (enExample)
CL (1) CL2015002181A1 (enExample)
EA (1) EA201591507A1 (enExample)
HK (2) HK1218251A1 (enExample)
IL (1) IL240014A0 (enExample)
MX (1) MX2015010296A (enExample)
PE (1) PE20151526A1 (enExample)
SG (1) SG11201505818WA (enExample)
TW (1) TW201442709A (enExample)
UY (1) UY35328A (enExample)
WO (1) WO2014127139A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106063787A (zh) 2012-02-03 2016-11-02 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
AR090885A1 (es) * 2012-05-02 2014-12-10 Teva Pharma Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
UY36099A (es) * 2014-04-29 2016-02-29 Teva Pharma Laquinimod para el tratamiento de pacientes con esclerosis múltiple remitente recurrente (rrms) con un alto grado de discapacidad
US10537566B2 (en) 2014-10-16 2020-01-21 Novartis Ag Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
US10091217B2 (en) 2016-06-21 2018-10-02 Logrhythm, Inc. Risk based priority processing of data
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
JP7193448B2 (ja) 2016-08-31 2022-12-20 マピ ファーマ リミテッド 酢酸グラチラマーを含むデポシステム
CN110382052A (zh) * 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
US20230296628A1 (en) * 2020-07-09 2023-09-21 Oklahoma Medical Research Foundation Biomarkers for Identifying Relapses in Multiple Sclerosis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
BRPI0713694A2 (pt) * 2006-06-12 2012-10-30 Teva Pharma composição farmacêutica, processo para preparar composição farmacêutica, embalagens vedada, métodos para tratar um indivìduo afligido com uma forma de esclerose múltipla, e para aliviar um sintoma de esclerose múltipla em um indivìduo afligido com uma forma de esclerose múltipla, e, uso da composição farmacêutica
BRPI0814624A2 (pt) * 2007-07-11 2015-01-27 Medicinova Inc Tratamento de doença neurodegenerativa progresiva com ibudilaste
TW201438738A (zh) * 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
BRPI0922871A2 (pt) * 2008-12-11 2016-11-16 Biovista Inc metodos para o tratamento da esclerose múltipla usando pirazinoindóis tetracíclicos
CN107308162A (zh) * 2009-06-19 2017-11-03 泰华制药工业有限公司 利用拉喹莫德治疗多发性硬化
UA111959C2 (uk) * 2010-12-07 2016-07-11 Тева Фармасьютікл Індастріз Лтд. Застосування лаквінімоду для зменшення втоми, поліпшення функціонального стану та поліпшення якості життя у пацієнтів з розсіяним склерозом
WO2013016686A1 (en) * 2011-07-28 2013-01-31 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and interferon-beta
AR090885A1 (es) * 2012-05-02 2014-12-10 Teva Pharma Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
EA201590726A1 (ru) * 2012-10-12 2015-10-30 Тева Фармасьютикал Индастриз Лтд. Лахинимод для уменьшения таламического поражения при рассеянном склерозе
UY36099A (es) * 2014-04-29 2016-02-29 Teva Pharma Laquinimod para el tratamiento de pacientes con esclerosis múltiple remitente recurrente (rrms) con un alto grado de discapacidad

Also Published As

Publication number Publication date
BR112015019564A2 (pt) 2017-07-18
CL2015002181A1 (es) 2016-06-03
EP2956137A1 (en) 2015-12-23
US20140235670A1 (en) 2014-08-21
PE20151526A1 (es) 2015-11-20
HK1218251A1 (zh) 2017-02-10
US20180064702A1 (en) 2018-03-08
CA2900503A1 (en) 2014-08-21
EP2956137A4 (en) 2016-08-03
TW201442709A (zh) 2014-11-16
JP2016510343A (ja) 2016-04-07
SG11201505818WA (en) 2015-08-28
IL240014A0 (en) 2015-09-24
AU2014216199A1 (en) 2015-09-03
CN105163737A (zh) 2015-12-16
HK1218254A1 (zh) 2017-02-10
EA201591507A1 (ru) 2015-12-30
KR20150119227A (ko) 2015-10-23
MX2015010296A (es) 2016-05-05
WO2014127139A1 (en) 2014-08-21

Similar Documents

Publication Publication Date Title
UY35328A (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod
CR20160308A (es) Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
NI201600071A (es) Compuestos de inhibidor de autotaxina
NI201600051A (es) Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
PH12015502075A1 (en) Treatment of cataplexy
MX370506B (es) Método para tratar trastorno de estrés post-traumático.
MX370664B (es) Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
MX2019009783A (es) Metodo para fabricar una barra que comprende antitranspirante.
MX365321B (es) Métodos para el tratamiento de neutropenia mediante agonistas retinoides.
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
MX2015012455A (es) Metodo para el tratamiento de la enfermedad de higado graso.
MX381429B (es) Tricostatina a (tsa) para usarse en el tratamiento del cáncer.
MX386151B (es) Uso de tricostatina a (tsa) en el tratamiento del mieloma múltiple.
AR094809A1 (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod
MX2017008879A (es) Composicion farmaceutica para el tratamiento de la micosis.
UY35748A (es) Terapia combinada con laquinimod para el tratamiento de la esclerosis múltiple
HK1227285A1 (en) Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma
NZ745950A (en) Methods and compositions for treating multiple sclerosis and related disorders
AR083637A1 (es) Composicion farmaceutica de combinacion para tratar enfermedades o condiciones asociadas a enfermedades neurodegenerativas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211105